Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Nelson

Physician Assistant, Medical Seattle, WA Physician Assistant

NPI 1265480818 CMS profile 10429842

4740 44Th Ave Sw, Ste 200, Seattle, WA 98116

Open in the dashboard

General payments

$14,976

557 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Nelson of Seattle, WA is reported in the CMS Open Payments database as having received $14,976 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,681 129
2024 General $4,926 145
2023 General $4,266 122
2022 General $1,576 90
2021 General $1,527 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Nelson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amy Nelson were reported at $2,681. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amy Nelson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,527 $156 $41–$563 $132
2022 $1,576 $185 $55–$649 $149
2023 $4,266 $199 $58–$717 $160
2024 $4,926 $206 $62–$740 $164
2025 $2,681 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,244 152 payments
  2. Janssen Biotech, Inc. $2,889 73 payments
  3. UCB, Inc. $2,664 60 payments
  4. E.R. Squibb & Sons, L.L.C. $1,012 33 payments
  5. Lilly USA, LLC $911 43 payments
  6. LEO Pharma Inc. $795 14 payments
  7. Arcutis Biotherapeutics, Inc. $718 13 payments
  8. Novartis Pharmaceuticals Corporation $625 54 payments
  9. Sun Pharmaceutical Industries Inc. $438 22 payments
  10. Regeneron Healthcare Solutions, Inc. $249 8 payments
  11. Other $1,431 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,067 547 payments
  2. Consulting Fee $3,573 4 payments
  3. Education $307 5 payments
  4. Travel and Lodging $30 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $2,640 59 payments
  2. Bimzelx $2,159 41 payments
  3. SKYRIZI $1,653 83 payments
  4. SOTYKTU $1,012 33 payments
  5. RINVOQ $857 37 payments
  6. ADBRY $795 14 payments
  7. Zoryve $702 12 payments
  8. TALTZ $646 31 payments
  9. Cimzia $463 18 payments
  10. SIMPONI ARIA $373 15 payments
  11. Other $4,786 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,007

Median for Physician Assistant: 241

Drug cost

$626,862

Median for Physician Assistant: $4,110

Branded share of claims

12.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 27 $219,916
Humira(Cf) Pen Adalimumab Brand 14 $195,005
Dupixent Pen Dupilumab Brand 18 $67,404
Otezla Apremilast Brand 14 $67,269
Xolair Omalizumab Brand 15 $46,423
Fluorouracil Generic 147 $8,966
Clobetasol Propionate Generic 94 $4,592
Doxycycline Hyclate Generic 83 $1,884
Tacrolimus Generic 18 $1,811
Tretinoin Generic 15 $1,300

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$135,224

Of which drugs: $10,994

Medicare patients

750

Average age 76

Services billed

3,876

480 women, 270 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 47%
Osteoporosis 19%
Atrial fibrillation 18%
Diabetes 16%
Ischemic heart disease 16%
Chronic kidney disease 15%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 44 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,803 — —
ADBRY
$525 — —
SOTYKTU
$403 — —
Bimzelx
$340 — —
SKYRIZI
$303 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record